Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG KIN-2787
- DRUG KIN-2787 and binimetinib
Study Locations (20)
California
- The Angeles Clinic — Los Angeles
- UCLA — Los Angeles
- University of California San Diego, Moores Cancer Center — San Diego
- University of California San Francisco — San Francisco
- Stanford Cancer Center — Stanford
Florida
- Mayo Clinic - Florida — Jacksonville
- Sarah Cannon Research Institute - Florida Cancer Specialists — Orlando
New Jersey
- Atlantic Health — Morristown
- Rutgers Cancer Institute of New Jersey — New Brunswick
New York
- NYU Langone — New York
- Memorial Sloan Kettering Cancer Center — New York
New South Wales
- Calvary Mater Hospital Newcastle — Waratah
- Melanoma Institute Australia — Wollstonecraft
Colorado
- Sarah Cannon Research Institute Denver — Denver
Minnesota
- Mayo Clinic - Rochester — Rochester
Ohio
- Cleveland Clinic — Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-08-04 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04913285
The ClinicalTrials.gov registry entry for NCT04913285 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pierre Fabre Medicament, which has 33 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions — of which KIN-2787 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04913285 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Florida, New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04913285 about?
NCT04913285 is a clinical study titled "A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
What is the current status of trial NCT04913285?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 400 participants. The study started on 2021-08-04. Estimated completion is 2029-03-30.
What conditions does trial NCT04913285 study?
This clinical trial studies the following conditions: Melanoma, Non-small Cell Lung Cancer, Solid Tumor, Adult. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04913285?
The interventions under investigation include: KIN-2787 (DRUG), KIN-2787 and binimetinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04913285?
This trial is sponsored by Pierre Fabre Medicament, which has 33 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04913285 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.